Grifols Sa Barc Ord New (GIFLF) Q1 2026 Earnings Call

Investor webinar replay

Replay transcript excerpt

Hello everyone and thank you for joining us today for Grifols' 4th Quarter 2026 Earnings Call. My name is Dani Segara and I serve as a Head of Investor Relations and Sustainability. Today I'm joined by Grifols' Chief Executive Officer, Nat Shabia, President of BioPharma, Roland Vandeler, and Chief Financial Officer, Rahul Isrubinabhasan. As is our usual practice, today's call will last about an hour. including the Q&A session. Please note that this call is being recorded. You can find additional materials, including today's presentation, in the investor relations section of the Grifols website at grifols.com. A transcript and reply of the webcast will also be available on the investor relations website within 24 hours. Turning to slide two, I would like to remind everyone that forward-looking statements may be made during this call. This may include, among other things, comments regarding the company's future operating and financial performance, statements about our future expectation, clinical developments, regulatory timelines, and the potential success of our product candidates. These statements are based on current expectations and available information as of the date of this call and are subject to certain risks and uncertainties that may cause actual results to differ materially from those discussed today. Grifols financial statements are prepared in accordance with EU IFRS and other applicable reporting provisions, including alternative performance measures, or APMs, as defined by European Securities and Markets Authority. Grifols management uses APMs to evaluate financial performance as the basis for operational and strategic decision making. These IPMs are prepared for all the time periods presented in this document. As announced on May 24, the Board of Dire...